The benefit of immunochemotherapy in treating resectable locally advanced non-small cell lung cancer (NSCLC) is not well established. Here, we report a case of resectable stage III NSCLC treated with neoadjuvant immunotherapy combined with chemotherapy before surgery. A 61 years old man was admitted to our hospital due to paroxysmal cough and was diagnosed as squamous cell carcinoma T4N2M0 in the upper lobe of the right lung, which was locally advanced and resectable. He was treated with 3 courses of paclitaxel 250 mg intravenous (IV), carboplatin 0.65 g IV, and durvalumab 620 mg IV followed by thoracoscopic upper lobectomy and lymph node dissection. There was considerable regression of the tumor before surgery, and the patient achieved a complete pathological response after surgery. Our case study demonstrates the benefit of durvalumab and chemotherapy in the treatment of resectable locally advanced NSCLC.

中文翻译：

---

新辅助免疫治疗联合化疗治疗局部晚期鳞状细胞肺癌1例报告及文献复习


免疫化疗在治疗可切除的局部晚期非小细胞肺癌（NSCLC）方面的益处尚未明确。在这里，我们报告一例术前接受新辅助免疫治疗联合化疗的可切除的 III 期 NSCLC 病例。一名61岁男性因阵发性咳嗽入院，诊断为右肺上叶鳞状细胞癌T4N2M0，局部晚期，可切除。他接受了 3 个疗程的紫杉醇 250 mg 静脉注射 (IV)、卡铂 0.65 g IV 和 durvalumab 620 mg IV 治疗，随后进行了胸腔镜上肺叶切除术和淋巴结清扫术。术前肿瘤已有相当程度的消退，术后患者获得完全的病理缓解。我们的案例研究证明了 durvalumab 和化疗在治疗可切除的局部晚期 NSCLC 中的益处。